about
Electrochemical, Electrochemiluminescence, and Photoelectrochemical Aptamer-Based Nanostructured Sensors for Biomarker AnalysisCancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancerToxin-based therapeutic approachesCirculating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.Cancer biomarker discovery: the entropic hallmark.Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment.Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessMicroRNAs associated with metastatic prostate cancerIdentification of an antibody fragment specific for androgen-dependent prostate cancer cells.Novel diagnostic biomarkers for prostate cancer.S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis.Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer.Microdevices integrating affinity columns and capillary electrophoresis for multibiomarker analysis in human serum.Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers.Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate CancerRNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings.Prostate cancer - a biomarker perspective.PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.Systematic, evidence-based discovery of biomarkers at the NCI.Appropriateness of Prostate Cancer Imaging among Veterans in a Delivery System without Incentives for Overutilization.The present and future of prostate cancer urine biomarkers.Clinically available RNA profiling tests of prostate tumors: utility and comparisonEmerging roles of human prostatic Acid phosphataseIdentification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis.Prostate cancer: the need for biomarkers and new therapeutic targets.Multiplexed detection of molecular biomarkers with phase-change nanoparticlesNovel biomarkers for the detection of prostate cancer.Vaccine-induced antibody responses in patients with carcinoma.Biosensor technology: recent advances in threat agent detection and medicine.Inflammation and prostate cancer: friends or foe?Anti-inflammatory effect and prostate gene expression profiling of steryl ferulate on experimental rats with non-bacterial prostatitis.Identification of microRNA signature and potential pathway targets in prostate cancer.The interaction of Wnt-11 and signalling cascades in prostate cancer.The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproateOn-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA.Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification.
P2860
Q26739039-3F858D16-FF5D-4E3B-A0D7-1BA24E21FF81Q26852766-BC03473B-E021-495B-BA90-3450FB7A83B2Q27013664-037E64A4-8BD8-42CF-A1E7-8E534FCB07CBQ27334654-EC8C3422-25DA-4F7B-8342-2E50630B0D05Q30496149-B0601A59-3929-40E9-88DC-83BFCA219D6EQ33592442-5E622A5C-5C30-404E-A2B7-F5FFE504D669Q33645816-6ADEF36A-AF9F-4A6B-8A3F-ABE6A20A0939Q33839248-A4A383A2-C573-4B08-8364-0A63880AAF14Q34042888-0EE7E7F4-AD6C-4E62-BA60-61ED065992B1Q34152258-3E29372B-A9E7-4933-9F17-32F36F769A9EQ34231678-174457BF-7DEC-46F7-96E7-8E31CA1DE50AQ34244767-317E3435-D6DA-4857-B98E-3E0C6DC98B73Q34356119-06D97633-53A1-42DA-B90F-855A6FE69C92Q34385535-A7898E96-0F30-49B2-AB45-2802DDC9C249Q34890107-E7E3D210-F9A0-465C-943B-147D891194FCQ35678391-F89F35FB-BADB-496D-8969-3C39B89C10FDQ35735074-ECA2908A-B095-40CC-87F9-81657032E4DEQ35932349-30AF4D0B-F218-4AC6-887F-456A94928925Q35992814-1285A063-6ECA-4615-8F46-C2FF52D0F5D2Q35993261-392EEE8B-958B-4B7A-B4F1-E04B2189EF6CQ35995359-3912921E-0F25-460D-A836-21EC88F64E67Q36290408-887EF6F9-58AC-4871-BDE9-94992600B446Q36922015-7A821AA0-8E3B-43F9-8A09-BC4AF31B32BDQ36922050-B564A5A7-04C3-4B84-A780-DE018C812375Q37007392-7B884A60-D8CA-444B-9965-67CE670E1D4EQ37113181-6CCCF97E-0B3A-40D4-ACDD-8496EA13E0C4Q37145460-FBB3D6CB-C292-4BF1-ABEA-015C6FB89958Q37160321-97F09EC8-80E8-4190-9191-3DEF46AFA7DEQ37476043-F1318E62-D645-427F-B928-F8EC2333A019Q37702599-E36494E1-ECFE-472D-8B56-12CBCFFC6592Q37708174-B0C1C1BA-7A7D-4E7B-8039-49A79002999BQ37762272-C26F3BDE-994B-4E2D-9275-1291387E233BQ38121489-746BF231-1BFA-4825-BF4B-1CF95C4E8109Q38383521-675292ED-2975-4047-B66B-32C885F0BDCDQ38478245-CD84F264-FA54-4620-AA03-96240E8C050EQ38728193-E96E2A28-D2FC-4A62-87E7-13F75E44440DQ38924969-8AC0D81D-BB55-4DF9-A219-F6D86A731857Q38987271-F95B84AD-BB2B-4FD3-9603-B87FCB07E20EQ39378788-8CA1E95E-EA6E-4BB7-86E6-DBF3EEF003C0Q39407375-368D78E9-5245-48F6-BF85-CB45A0950F53
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Biomarkers for prostate cancer.
@en
type
label
Biomarkers for prostate cancer.
@en
prefLabel
Biomarkers for prostate cancer.
@en
P50
P1476
Biomarkers for prostate cancer.
@en
P2093
Robert H Getzenberg
P304
P356
10.1146/ANNUREV.MED.60.042307.110714
P577
2009-01-01T00:00:00Z